Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2015; 6(6): 202-206
Published online Dec 10, 2015. doi: 10.5306/wjco.v6.i6.202
Published online Dec 10, 2015. doi: 10.5306/wjco.v6.i6.202
Sentinel lymph node metastasis after neoadjuvant treatment in breast cancer: Any size matters?
Isabel T Rubio, Breast Surgical Oncology Unit, Breast Cancer Center, Hospital Universitario Vall d’Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
Author contributions: Rubio IT had contributed to all parts of the manuscript.
Conflict-of-interest statement: No conflict of interest to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Isabel T Rubio, MD, PhD, Breast Surgical Oncology Unit, Breast Cancer Center, Hospital Universitario Vall d’Hebron, Universitat Autònoma de Barcelona, Paseo Vall d’Hebron 119, 08035 Barcelona, Spain. irubio@vhio.net
Telephone: +34-93-2894286
Received: May 25, 2015
Peer-review started: May 27, 2015
First decision: August 4, 2015
Revised: August 9, 2015
Accepted: September 25, 2015
Article in press: September 28, 2015
Published online: December 10, 2015
Processing time: 198 Days and 4 Hours
Peer-review started: May 27, 2015
First decision: August 4, 2015
Revised: August 9, 2015
Accepted: September 25, 2015
Article in press: September 28, 2015
Published online: December 10, 2015
Processing time: 198 Days and 4 Hours
Core Tip
Core tip: One of the advantages of neoadjuvant chemotherapy treatment in breast cancer is to downstage positive axillary nodes to negative. Postneoadjuvant sentinel lymph node (SLN) has been increasingly used and randomized studies in patients with positive axillary nodes who convert to node negative have shown that false negative rates are highly influenced by the surgical technique. Information from these studies has shown that isolated tumor cells in the SLN, when considered as positive nodes, lower false negative rates. Whether any residual disease in the SLNs may have prognostic implications warrants further research.